This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

LONDON (Reuters) - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...